Tagworks Pharmaceuticals BV (“Tagworks”), the pioneer of Click-to-Release chemistry designed to deliver more effective and safer systemic therapies, today announced a $65 million Series A financin...
Read moreVHIO researchers publish an editorial on the preliminary results of a phase 1 clinical trial testing a novel SHP2 inhibitor. The clinical trial data discussed in the editorial represent a paradigm shi...
Read moreThis collaboration allows combining experience and resources for the discovery and development of new therapies.
Read moreβ-cyclodextrins prevent SARS-CoV-2 and HCoV-229E infection in cell cultures, primary tissues and animal model
Read moreEl fármaco experimental vorasidenib retrasa el crecimiento de los gliomas con mutaciones en genes IDH, concluye un ensayo clínico realizado por investigadores del Memorial Sloan Kettering Cancer Cen...
Read moreOncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, today announced the closing of a Round C financing of 6,5 ...
Read moreThe Spanish Agency of Medicines and Medical Devices has authorised the clinical trial of IDP-121, the first drug blocking and degrading a key oncoprotein in several hematological tumors, including mul...
Read moreOryzon Genomics today reports new preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BDP).
Read moreEl síndrome del ojo seco es una enfermedad multifactorial de la superficie ocular caracterizada por la pérdida de la película lagrimal y el deterioro de su calidad, que producen en muchos casos una...
Read moreBeyond the Pill es un término holístico centrada en el paciente donde la salud y bienestar de una persona va más allá de simplemente tomar una píldora o medicamento y engloba la tecnología de la...
Read moreA collaboration has been signed between the Bellvitge Biomedical Research Institute (IDIBELL), the Institute of Cancer Research (ICR) in London, and Vivan Therapeutics to jointly develop molecules tha...
Read moreResearcher has been able to verify that the combination of two drugs, enfortumab vedotin and pembrolizumab, which had previously shown benefits in survival in second-line treatment and in cases of adv...
Read more